A 35-year-old woman presents to the outpatient clinic with a 6-month history of progressive dyspnea on exertion and palpitations. She has a 10-year history of uncontrolled hypertension (BP 160/100 mmHg on today's visit). Physical examination reveals a sustained apical impulse displaced 2 cm lateral to the midclavicular line, and a grade 2/6 systolic murmur at the apex. Echocardiography shows concentric left ventricular hypertrophy with preserved ejection fraction and normal wall motion. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: Hypertensive Heart Disease with LV Hypertrophy This patient demonstrates **concentric left ventricular hypertrophy (LVH)** — a cellular adaptation to chronic pressure overload from uncontrolled hypertension. The heart responds to sustained elevated afterload by increasing myocyte size (hypertrophy) and increasing myocyte number per unit area (relative hyperplasia of connective tissue), resulting in a thickened left ventricle with preserved cavity size. ### Pathophysiology of Hypertensive LVH **Key Point:** Concentric LVH is a compensatory adaptation that initially maintains cardiac output despite increased wall stress, but chronic hypertrophy leads to diastolic dysfunction, fibrosis, and eventual systolic failure if the stimulus (hypertension) is not removed. **High-Yield:** The fundamental mechanism is: 1. Chronic hypertension → increased afterload 2. Increased wall stress (Laplace's law: σ = Pr/2h) 3. Myocyte hypertrophy to normalize wall stress 4. Progressive interstitial fibrosis and diastolic dysfunction ### Management Algorithm ```mermaid flowchart TD A[Concentric LVH + Uncontrolled HTN]:::outcome --> B{BP controlled?}:::decision B -->|No| C[Initiate/optimize antihypertensive therapy]:::action B -->|Yes| D[Assess for complications] C --> E[ACE-I/ARB preferred: regress LVH]:::action E --> F[Repeat echo in 6-12 months]:::action D --> G{Diastolic dysfunction present?}:::decision G -->|Yes| H[Add beta-blocker or CCB]:::action G -->|No| I[Continue medical management]:::action ``` ### Why ACE Inhibitor is First-Line | Feature | ACE-I/ARB | Beta-Blocker | Calcium Channel Blocker | |---------|-----------|--------------|------------------------| | **BP reduction** | ✓ | ✓ | ✓ | | **LVH regression** | ✓✓ (best) | ✓ | ✓ | | **Mechanism** | Reduces afterload + anti-remodeling | Reduces contractility | Reduces afterload | | **Diastolic function** | Improves | Improves | Improves | | **First-line in HTN** | Yes | Yes (if CAD/post-MI) | Yes (if contraindication) | **Clinical Pearl:** ACE inhibitors and ARBs are superior to other antihypertensives for **regression of established LVH** because they reduce afterload AND directly inhibit cardiac fibrosis via angiotensin II blockade. This addresses both the hemodynamic stimulus and the molecular drivers of hypertrophy. **Key Point:** With preserved ejection fraction and no acute decompensation, the immediate priority is **controlling the stimulus** (hypertension) to halt further hypertrophy and prevent progression to systolic dysfunction. Invasive procedures are not indicated at this stage. [cite:Robbins 10e Ch 1; Harrison 21e Ch 242]